Morgan Stanley lowered its position in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 21.7% during the first quarter, Holdings Channel reports. The institutional investor owned 660,102 shares of the biopharmaceutical company’s stock after selling 182,525 shares during the period. Morgan Stanley’s holdings in Inovio Pharmaceuticals were worth $4,370,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Stoneridge Investment Partners LLC boosted its stake in shares of Inovio Pharmaceuticals by 0.8% in the first quarter. Stoneridge Investment Partners LLC now owns 254,449 shares of the biopharmaceutical company’s stock worth $1,684,000 after buying an additional 2,073 shares in the last quarter. American International Group Inc. boosted its stake in shares of Inovio Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 40,856 shares of the biopharmaceutical company’s stock valued at $270,000 after buying an additional 2,695 shares during the period. Teachers Advisors LLC boosted its stake in shares of Inovio Pharmaceuticals by 2.3% in the first quarter. Teachers Advisors LLC now owns 151,775 shares of the biopharmaceutical company’s stock valued at $1,005,000 after buying an additional 3,411 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Inovio Pharmaceuticals by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 342,348 shares of the biopharmaceutical company’s stock valued at $2,266,000 after buying an additional 11,765 shares during the period. Finally, Vident Investment Advisory LLC boosted its stake in shares of Inovio Pharmaceuticals by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 127,375 shares of the biopharmaceutical company’s stock valued at $843,000 after buying an additional 21,228 shares during the period. Institutional investors and hedge funds own 22.92% of the company’s stock.

Inovio Pharmaceuticals, Inc. (NASDAQ INO) traded up 1.28% during mid-day trading on Friday, reaching $5.56. The company’s stock had a trading volume of 1,077,056 shares. Inovio Pharmaceuticals, Inc. has a 12 month low of $5.32 and a 12 month high of $9.86. The company’s market cap is $501.66 million. The stock’s 50 day moving average is $6.81 and its 200 day moving average is $6.81.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.08. Inovio Pharmaceuticals had a negative return on equity of 63.67% and a negative net margin of 153.46%. The firm had revenue of $20.41 million for the quarter, compared to analyst estimates of $16.29 million. During the same quarter in the prior year, the firm posted ($0.26) earnings per share. The company’s quarterly revenue was up 229.2% on a year-over-year basis. Equities research analysts predict that Inovio Pharmaceuticals, Inc. will post ($0.93) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.watchlistnews.com/inovio-pharmaceuticals-inc-nasdaqino-position-decreased-by-morgan-stanley/1479006.html.

Several brokerages have commented on INO. ValuEngine upgraded shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday. HC Wainwright set a $13.00 price target on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday. Maxim Group set a $12.00 price target on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday. BidaskClub cut shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Finally, Aegis reiterated a “buy” rating and issued a $14.00 price target on shares of Inovio Pharmaceuticals in a research report on Tuesday, July 18th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $20.78.

In other Inovio Pharmaceuticals news, Director David B. Weiner sold 8,000 shares of the stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $8.00, for a total value of $64,000.00. Following the transaction, the director now owns 740,956 shares of the company’s stock, valued at $5,927,648. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 10.60% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Want to see what other hedge funds are holding INO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inovio Pharmaceuticals, Inc. (NASDAQ:INO).

Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.